The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: esraa mohamed abdallah, teaching assistant
- Phone Number: 01019976442
- Email: ema17@fayoum.edu.eg
Study Contact Backup
- Name: marwa kamal tolba, assistant professor
- Phone Number: 01067789982
- Email: mka05@fayoum.edu.eg
Study Locations
-
-
-
Al Fayyum, Egypt
- Fayoum University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience:
- Dizziness or fainting
- Heart palpitations, which may feel like your heart fluttering or skipping beats
- Shortness of breath
Exclusion Criteria:
- Patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications.
- Individuals with contraindications to the use of sildenafil or dapagliflozin.
- Patients with pulmonary arterial hypertension (PAH) due to conditions other than heart failure (e.g., idiopathic PAH).
- severe hepatic impairment
- aged less than 18 years.
- valvular heart disease .
- Patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures.
- life expectancy of less than 6 months .
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: control group
|
Control group: receive dapagliflozin in addition to standard therapy
|
|
Active Comparator: test group
|
Control group: receive dapagliflozin in addition to standard therapy
Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in ejection fraction
Time Frame: 12 weeks after treatment
|
Determine the influence of sildenafil as an add-on to dapagliflozin on Left ventricular ejection fraction using function using echocardiography
|
12 weeks after treatment
|
|
change in systolic pulmonary artery pressure
Time Frame: 12 weeks after treatment
|
Determine the influence of sildenafil as an add-on to dapagliflozin on systolic pulmonary artery pressure using echocardiography
|
12 weeks after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Heart Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Heart Failure
- Hypertension
- Hypertension, Pulmonary
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Amides
- Purines
- Sulfonamides
- Sulfones
- Piperazines
- Sildenafil Citrate
- dapagliflozin
Other Study ID Numbers
Other Study ID Numbers
- M 722
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.